ArticleNature communications2023
Real-time environmental surveillance of SARS-CoV-2 aerosols.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Machine-Learning Microfluidic Minute-Scale Microorganism Metrics Monitoring(M6).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Waterborne pathogen mitigation: Decoding techno-ecological synergies in multiscale transmission networks.Innovation (Cambridge (Mass.)) · 2026Review
- The Selective Detection of Individual Respiratory Droplets in Air.ACS sensors · 2026Article
- Beyond Diagnosis: Aerosol Viral Monitoring to Transform Epidemic Responses.Research (Washington, D.C.) · 2026Review
- A Cloud-Based Platform for Harmonized COVID-19 Data: Design and Implementation of the Rapid Acceleration of Diagnostics (RADx) Data Hub.JMIR public health and surveillance · 2025Article
- A Microfluidic Chip-Based Integrated Device Combining Aerosol Sampling and LAMP-CRISPR Detection for Airborne Virus Surveillance.Biosensors · 2025Article
- Capacitive Biosensor for Rapid Detection of Avian (H5N1) Influenza andACS sensors · 2025Article
- On-Site Dual Detection of AirborneMicroorganisms · 2025Article
- Multi-scenario surveillance of respiratory viruses in aerosols with sub-single-copy spatial resolution.Nature communications · 2024Article
- Recent Advances in Development of Biosensors for Monitoring of Airborne Microorganisms.Iranian journal of biotechnology · 2024Review
- Digital Surface-Enhanced Raman Spectroscopy-Lateral Flow Test Dipstick: Ultrasensitive, Rapid Virus Quantification in Environmental Dust.Environmental science & technology · 2024Article
- Ventilation-Based Strategy to Manage Intraoperative Aerosol Viral Transmission in the Era of SARS-CoV-2.Life (Basel, Switzerland) · 2024Article
- Post COVID-19 Reflections and Questions: How Prepared Are We for the Next Pandemic?International journal of molecular sciences · 2024Article
- Article
- Reduction of acute respiratory infections in day-care by non-pharmaceutical interventions: a narrative review.Frontiers in public health · 2024Review
- The time has come to protect healthcare workers and patients from aerosol transmissible disease.Frontiers in public health · 2024Article
- On-site airborne pathogen detection for infection risk mitigation.Chemical Society reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Real-time surveillance of airborne SARS-CoV-2 virus is a technological gap that has eluded the scientific community since the beginning of the COVID-19 pandemic. Offline air sampling techniques for SARS-CoV-2 detection suffer from longer turnaround times and require skilled labor. Here, we present a proof-of-concept pathogen Air Quality (pAQ) monitor for real-time (5 min time resolution) direct detection of SARS-CoV-2 aerosols. The system synergistically integrates a high flow (~1000 lpm) wet cyclone air sampler and a nanobody-based ultrasensitive micro-immunoelectrode biosensor. The wet cyclone showed comparable or better virus sampling performance than commercially available samplers. Laboratory experiments demonstrate a device sensitivity of 77-83% and a limit of detection of 7-35 viral RNA copies/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.